Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

ما

معاذ السفياني

@MuathSufyani · X

أول حبّة GLP-1 فموية غير ببتيدية لتنزيل الوزن والسكر ‼️ ? أورفورغليبرون (Orforglipron): هو حبة تؤخذ عن طريق الفم (مو إبرة)، تشتغل زي أدوية GLP-1 اللي تقلل السكر وتساعد على التنحيف، لكن بميزة إنه مو ببتيدي (يعني تركيبته مختلفة عن الإبر زي سيماغلوتيد (Semaglutide) و تيرزيباتيد (Tirzepatide) ? آلية العمل (Mechanism of Action): حبّة أورفورغليبرون تشتغل على مستقبل GLP-1، وتساعد الجسم على: • زيادة إفراز الإنسولين وقت الحاجة • تقليل الجلوكاجون • تأخير إفراغ المعدة • تقليل الشهية وزيادة الإحساس بالشبع وتتميز إنها تشتغل على إشارات cAMP أكثر من إشارات البيتا-أريستين، وهذا ممكن يعطي فعالية أطول وأعراض جانبية أقل. ? نتائج قوية في السمنة (Obesity): 1️⃣ الدراسة الأولى: Susan Wharton et al., NEJM 2023، عنوان الدراسة: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? دراسة من المرحلة الثانية (عشوائية ومزدوجة التعمية) شملت 272 شخص يعانون من السمنة (BMI ≥30): ✅ بعد 36 أسبوع: •

N

NEJM

@NEJM · X

Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists? https://t.co/gbnfDsdQOL https://t.co/Jj8BJEhDV2

SI

Scott Isaacs

@scottisaacsmd · X

Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with -9.4% to -14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/W76gyKF1zJ

دم

د.سلطان مشعل

@drsultanrabie · X

@SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/om9ymEVO7z

N

NEJM

@NEJM · X

Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https://t.co/4kvka2Zwo1

SW

sean wharton

@seanwharton · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a significant advancement in medicine. This will improve access to care. #ada2023 https://t.co/ChwqtRQeMn

LR

Lumina Research

@luminaresearch6 · X

Lilly is the first $1T drugmaker. Dave Ricks skipped the victory lap and picked fights: • GLP-1s at ~8–9% US penetration aren't peaking • 1% vs 50–80% oral bioavailability • "Muscle loss crisis" is a DEXA artifact • Buy biotechs, don't gut them ? https://t.co/6cxPlqsL4o

MN

Mega Doctor News

@MegaDoctor · X

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems. #fda #FdaApproval #foundayo #glp_1 https://t.co/kYjF71B06s

E

EASO

@EASOobesity · X

The Food and Drug Administration @FDAMedWatch has approved @EliLillyandCo’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems. This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025. @mnt

MN

Mega Doctor News

@MegaDoctor · X

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems. #fda #FdaApproval #foundayo #glp_1 https://t.co/kYjF71B06s

GL

GLP-1 LIFE!

@GLP1_LIFE · X

#foundayo #glp1 #orforglipron #elilly https://t.co/OQciSLnopa

자원

자연철학의 수학적 원리

@NaturaPrinciple · X

https://t.co/SW0j7JZcBL

AP

Abdulla A. Damluji, MD, PhD

@DrDamluji · X

@JCanNuSH @NEJM Thank you Should have said glp1 agonist https://t.co/fbdUUlMRQr

DM

Dr Andrew Mitchell

@mitcharj · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/l5xozzPBuh via @NEJM

J

Joanne

@joannefirth.bsky.social · Bluesky

Great read! www.nejm.org/doi/full/10....

NK

Nikos Karamalis

@KaramalisNikos · X

@dikoros2 @Pierrakakis Που να δεις και σε λίγο που θα ειναι σε χαπάκια κι όχι ενέσιμα https://t.co/8XdakvObOR

C

Crémieux

@cremieuxrecueil · X

Also, while I think Viking won't launch with the empty stomach/fasting requirement, AFAIK, it's unconfirmed. Weird, no? I am also curious about titration between orals and injectables. Sources: https://t.co/b4Rhcbffjs https://t.co/PxoOaDpIWZ https://t.co/0bK87iY7ft

T

TF2

@Barry3252181 · X

P2 $LLY Orforglipron Vomiting Data - 2nd line down - much more significant than $VKTX VK2735https://www.nejm.org/doi/full/10.1056/NEJMoa2302392 https://t.co/DwMIub4KH9

T

TF2

@Barry3252181 · X

RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…

PN

Pisma iz NorveškU

@zonjce · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/3epGleCst6

TA

tp53 (ashish)

@inventcures · X

RT @skathire: New GLP1 Agonist orfoglipron - once daily - oral - non-peptide - no food or water restriction 2 Phase 2 trials Weight: up…

Z

Zero’

@xero990 · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

با

بنت احمد

@nn24_s · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

عق

عزيز قوم

@Odao5005 · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

Ø

ØÀMŘ

@Omar9n9 · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

ما

معاذ السفياني

@MuathSufyani · X

أول حبّة GLP-1 فموية غير ببتيدية لتنزيل الوزن والسكر ‼️ ? أورفورغليبرون (Orforglipron): هو حبة تؤخذ عن طريق الفم (مو إبرة)، تشتغل زي أدوية GLP-1 اللي تقلل السكر وتساعد على التنحيف، لكن بميزة إنه مو ببتيدي (يعني تركيبته مختلفة عن الإبر زي سيماغلوتيد (Semaglutide) و تيرزيباتيد (Tirzepatide) ? آلية العمل (Mechanism of Action): حبّة أورفورغليبرون تشتغل على مستقبل GLP-1، وتساعد الجسم على: • زيادة إفراز الإنسولين وقت الحاجة • تقليل الجلوكاجون • تأخير إفراغ المعدة • تقليل الشهية وزيادة الإحساس بالشبع وتتميز إنها تشتغل على إشارات cAMP أكثر من إشارات البيتا-أريستين، وهذا ممكن يعطي فعالية أطول وأعراض جانبية أقل. ? نتائج قوية في السمنة (Obesity): 1️⃣ الدراسة الأولى: Susan Wharton et al., NEJM 2023، عنوان الدراسة: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? دراسة من المرحلة الثانية (عشوائية ومزدوجة التعمية) شملت 272 شخص يعانون من السمنة (BMI ≥30): ✅ بعد 36 أسبوع: •

A

Alodhri

@Alodhri · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

A

Ahmad

@Ahmad45473028 · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

فا

فهد المغربي ابويزيد

@fahadfund · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

F

Faaa

@Faaa35163497 · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

A

Ahmed

@Ahmed181993m · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

اا

ابونايف العتيبي

@abo_naifea · X

RT @drsultanrabie: @SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/…

دم

د.سلطان مشعل

@drsultanrabie · X

@SaudiNews50 اسم الدواء orforgliprone اورفورقليبرون وهو دواء يستخدم لخفض السكر و نشر عنه انه يخفض الوزن .. https://t.co/om9ymEVO7z

TW

The WhyGuy

@thewhy6uy · X

@thisisamammad https://t.co/JUFh3NPLa3

TW

The WhyGuy

@thewhy6uy · X

@mooooonlighgir https://t.co/JUFh3NPLa3

دح

دیکتاتور حانیه

@hanieh35 · X

RT @thewhy6uy: دوستان تا مدتی بعد امکان داره قرص خوراکی با اثر مشابه اوزمپیک بیاد به بازار. قیمت میاد پایین و بنظرم بشدت نتایجش در سطح جامع…

TW

The WhyGuy

@thewhy6uy · X

دوستان تا مدتی بعد امکان داره قرص خوراکی با اثر مشابه اوزمپیک بیاد به بازار. قیمت میاد پایین و بنظرم بشدت نتایجش در سطح جامعه جذاب خواهد بود. در موردش بخونید وقت داشتین. https://t.co/E4BSlxvMwa

OO

O. Stephen Ojo

@Ojo_CHEM · X

danuglipron was discontinued but orforglipron awaits approval. #GLP-1Agonists #weightloss #type2diabetes Phase 2 study: DOI: 10.1056/NEJMoa2302392 Phase 3 trials: https://t.co/RVsesOcRMu https://t.co/SPZEaXhCfl

J

Joanne

@joannefirth.bsky.social · Bluesky

The full trial study of Eli Lilly's miracle pill. Via NEJM. www.nejm.org/doi/full/10....

M

@MomD

@minddr · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/HFYHKQJtJR

D糖

Dr.U@糖尿病メモ

@dr_ukio · X

■ファイザー、 経口GLP-1「ダヌグリプロン」開発中止 ファイザーが開発中の低分子経口GLP-1「ダヌグリプロン」の開発中止を発表。 これで食事制限なし経口GLP-1の開発は、リリーの「オルフォグリプロン」のみになります。 https://t.co/Yok98iBzB1

T

TF 2

@TonyFauci2 · X

RT @TonyFauci2: $LLY Safety Fail: “nausea ranged from 37% to 58% across the orforglipron dose cohorts and was 10% in the placebo group. The…

T

TF 2

@TonyFauci2 · X

$LLY Safety Fail: “nausea ranged from 37% to 58% across the orforglipron dose cohorts and was 10% in the placebo group. The incidence of vomiting ranged from 14% to 32% with orforglipron” $VKTX safest. https://t.co/AzB6YoSfdR

AM

Alessio Minuzzo

@alessiominuzzo · X

È stata dimostrata una riduzione del peso dell’8%. 5/ https://t.co/EMo0vCHeQT

O

Ondo(✸,✸)

@ArianaPantasy · X

RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…

T

TF 2

@TonyFauci2 · X

RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…

H

Hardest

@Hardestman9 · X

RT @YAYshamsaldeen: @LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي

اا

الأنيميا المنجلية @

@Sikclecell · X

RT @YAYshamsaldeen: @LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي

دا

د. يوسف شمس الدين

@YAYshamsaldeen · X

@LillyPad @US_FDA @EliLillyandCo متوقع في شهر أغسطس٢٠٢٥، ظهور نتائج التجارب الإكلينيكية المرحلة3️⃣للدواء التجريبي

G

Giorgio

@DaddySugarCanee · X

RT @TonyFauci2: $LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with…

T

TF 2

@TonyFauci2 · X

$LLY new oral Obesity Candidate has much worse safety profile than does $VKTX Oral VK2735 - $LLY - nausea, 37 to 58% with orforglipron and 10% with placebo; for vomiting, 14 to 32% with orforglipron and 6% with placebo https://t.co/AzB6YoRHoj $VKTX - “Mild nausea was reported

LK

Leon Katz

@DrLeonKatz · X

Oral GLP-1 Weight Loss Medications: A New Frontier in Obesity Treatment ?? Recent developments in oral GLP-1 (Glucagon-Like Peptide-1) weight loss medications have sparked considerable interest in both scientific and public spheres. This article explores the current landscape of these medications and their potential to revolutionize obesity treatment. ? The Challenge of Oral Medications ? To understand the excitement surrounding oral GLP-1 medications, it's crucial to recognize the challenges associated with oral drug administration: 1.    Digestive Breakdown: Oral medications must survive the harsh environment of the stomach and intestines, where some of the active ingredient is lost. ? 2.    Hepatic Metabolism: The liver further processes the remaining medication, reducing the amount of active compound that reaches target organs. ? 3.    Reduced Efficacy: Consequently, the dose reach

CS

CUN Surgery

@cun_surgery · X

@doctorValenti @fjavesc @Nature @JAMA_current @JAMASurgery @obesidadSECO @aec_obesidad @TheLancet @NEJM @ctueroo

SS

Swapnil Hiremath @hswapnil.medsky.social

@hswapnil · X

@Jwaitz @ChristosArgyrop @thisis_drgsp @NephroSeeker @arvindcanchi How about this molecule? @LittleBigGloms Orforglipron from Eli Lilly https://t.co/NtQeoiMHpA (Yeah likely to be costly but syringe needle supply issues will be less) #NephJC https://t.co/OASvJzwVwW

AM

Anil Makam

@AnilMakam · X

@Factor_XII trial https://t.co/TUxqESHBsy

AD

An Margarita Durán

@AnMargaritaDur1 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine https://t.co/1iECynVtwD

C

christopher

@christoph_929 · X

RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…

M

Murali

@grumpeoldman · X

RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…

DW

Dr Murphy WeightLoss

@TakeWeightOffMD · X

RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…

DM

Drdevi kalyan mishra

@KalyanDevi · X

RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…

DV

Dr. VK

@fanoffortywinks · X

RT @RajeevJayadevan: Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it.…

RJ

Rajeev Jayadevan

@RajeevJayadevan · X

Orforglipron is an oral partial GLP-1 agonist found to reduce 10% weight within 6 months in about 3/4 people using it. The drop out rate due to gastrointestinal side effects was 10-17% in this RCT. https://t.co/r45xizTApw https://t.co/t3tKPmhoN4 https://t.co/WAXzX452Rs

O

ONE

@YuZhu4 · X

RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…

O

optionsplayer

@optionsplayer18 · X

RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…

AA

Ani Anirudhan

@pnani456 · X

RT @semodough: $LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moder…

D

dough

@semodough · X

$LLY analyst take $LLY's Phase 2 orforglipron data shows similar change weight loss at week 4, caveat: shows more mild/moderate nausea/GI events compared to Phase 1 VK2735. $VKTX Tolarabity Tolarabity Tolarabity https://t.co/dSJw2MDS0P

DP

Dr Ramdas Pananthattil

@PananthattilR · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

EF

Endo Fellow

@endo_fellow · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

TK

T.kimura

@jjcrazydiamond · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

J

JorgeEdoChava75

@QicenoJorge · X

RT @ZHeart11768530:

S

Sky

@clinicontw · X

RT @ZHeart11768530:

P

Pamela

@Pachudecloset · X

RT @ZHeart11768530:

M

Mana

@manasigh · X

RT @ZHeart11768530:

SA

Sintayehu Abebe

@sinta_gf · X

RT @ZHeart11768530:

DL

dktor_laith

@dktor_laith · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

NH

Naeem ul Hassan

@naeemulhassan_ · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

EE

Elham Elmehdawi

@Elham1549664 · X

RT @ZHeart11768530:

HC

Habib Cissé

@Kissiland_man · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

WE

Wael Metwally Elsayed

@wisevision2010 · X

RT @ZHeart11768530:

GJ

Gautam Jain

@GautamJ45800509 · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

A

Alexo

@alexoterov · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

SK

sejal kotwani

@KotwaniSejal · X

RT @NEJM: 3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinolog…

N

NEJM

@NEJM · X

3. Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #Endocrinology https://t.co/Raibrrc8et

S

Sulmaaz

@SulmaazQ · X

RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…

UA

Umaira Aziz

@documi · X

RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…

دس

د. فيصل الجهني استشاري غدد صماء و سكري و سمنة

@Fajehani · X

RT @scottisaacsmd: Daily oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse…

MS

M.S

@motoshingu · X

RT @ringo_diabetes: 現在経口のGLP1RAはリベルサスのみですが内服時の注意事項が多く吸収が不安定な点がデメリットとして挙げられます。今後発売が期待されている新たな低分子GLP1RAとしてはPfizerのDanuglipron、Lilyのorforglipr…

り

りんご

@ringo_diabetes · X

現在経口のGLP1RAはリベルサスのみですが内服時の注意事項が多く吸収が不安定な点がデメリットとして挙げられます。今後発売が期待されている新たな低分子GLP1RAとしてはPfizerのDanuglipron、Lilyのorforglipronが2相まで通過しています。 https://t.co/AJngsesl0i https://t.co/ti08nUYkqg

G

GratefulCompounder

@GCompounder · X

As $VKTX runs another 5% today, if it seems the obesity/metabolic drug space is crowded, think again. $LLY is attempting to pre-solve for the supply constraint expected for the oral version of these meds. https://t.co/1IRzPWGyiS

PR

Paolo Ruggiero

@RuggieroPaol · X

RT @EricTopol: At #ADA2023 and @NEJM today @AmDiabetesAssn A GLP-1 pill randomized trial for weight loss https://t.co/JyPRGduP0g Not as mu…

SI

Scott Isaacs

@scottisaacsmd · X

Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight loss of almost 15% with similar side effects to injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/k38EBAe9dQ

DA

dr.ashry

@ashrymahmod · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

MB

Myriam Beaulieu

@DraMyriambo10 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

L

lal0155

@lal0155 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

NS

Nicolas D. Santoyo S

@NicolasSantoyoS · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

KV

Klp Vaishnavi

@VaishnaviKlp · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

P

Parth

@flozinatorMD · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

A

antoniofagundesjr

@fagundes_anton · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

VH

Victor Hernández

@VicHdez27 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

NR

Natsir Ramadhan

@natsiradhan · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

EJ

Ellie Jones

@_ELLIE_JONES_x · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

AN

A. Noal

@riannoal · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

HR

Hany Ragy

@Hragy · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

VS

V.N.Vignesh Shantham

@Trucebreaker13 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

CD

Carlos Dueñas

@CarlosJ_Duenas · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

CS

Cándido Sánchez

@CandidoSanchez_ · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

IE

Ivan Quispe Marca. MD, EM

@Drivanqm · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DS

Dr Owais Shahid

@Owaeyss · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

AA

Ahmed Alaa

@DrAhAlaMo · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DL

Dr Victor Lin

@victorshiyulin · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

BT

Bala Tangiisuran

@DrTangiisuran · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

A

Asger

@_camilobrochero · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

VT

Vincent Anthony Tang

@VASTangMD · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

TD

Türk Karaciğer Araştırmaları Derneği

@tkadorg · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DV

Dr. Christian Velasquez

@drchvelasquezb · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

JW

Jamie Wang

@jamiewang1228 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

จอ

จ๋อง

@panupong_mtnd · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

PA

Putu Aditya

@putu_aditya · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

RC

Rodrigo Nunes Cal

@CalZole · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

E

evinbozcali

@ebozcali · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DA

Dr.Yousef Alalawi

@yousefM6 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

BN

Benito Navarrete

@BenNavarrete · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DG

Dr. Robert Glatter

@DrRobertGlatter · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DF

Dr.FernandoRuiz

@Ferruita · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

ES

Elías Sabán

@eliassaban98 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

S

Sherif

@Sherifdotcom · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

A

anymzcs

@anymzcs · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

EM

Eve Beavers-Fain BSN MPH

@espacetimeNOT · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

CÁ

Carlos Ávila

@CarlosAR016 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

BJ

Bayar Jaff

@JaffBayar · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

H

Helga

@Aisha12895124 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

NH

Naeem ul Hassan

@naeemulhassan_ · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

FH

Francisco J Hidalgo

@PocimeroSF · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

BD

Blanca Lizaola-Mayo, MD, DABOM

@Blankmd22 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

AW

akho wey

@__peacebeyondme · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DA

Dr. Akhil

@DrAkhilX · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

FP

Food&Pharma

@rengerwitkamp · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

CP

Colorful MD Phd

@FanYang38636272 · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DM

Daniel Martín

@DaniMartinENDO · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

DE

Dr. Hugo Corrales - Endocrinología.

@hugoendocrino · X

RT @scottisaacsmd: Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated wit…

SI

Scott Isaacs

@scottisaacsmd · X

Number 10 Top Cardiometabolic Story of 2023: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with -9.4% to -14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEICej https://t.co/W76gyKF1zJ

N

NursePatsy

@PatsyDiabetes · X

RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…

AP

Anneke Palsma

@AnnekePalsma · X

RT @rengerwitkamp: Farma juicht, voeding siddert en aandelen worden herbelegd. De nieuwe oraal toe te passen GLP-1 agonisten en krachtige T…

TF

The Cardiometabolic Forum

@theCMforum · X

Wharton et al. reported that treatment with #orforglipron resulted in weight reduction and related benefits similar to efficacy outcomes observed with injectable GLP-1RAs, already approved for weight management. Learn more on the CMF today: https://t.co/2ENPRwPV7Z

SI

SID Italia

@Sid_Italia · X

Journal Club SID Trattamento dell’obesità: arrivano anche le formulazioni orali? - A cura di Danila Capoccia https://t.co/Y2FO8eiD9W

TF

The Cardiometabolic Forum

@theCMforum · X

Wharton, et al. reported that treatment with #orforglipron resulted in weight reduction and related benefits similar to efficacy outcomes observed with injectable GLP-1RAs that have already been approved for weight management. Learn more on the CMF: https://t.co/J03jQs6sV6

TF

The Cardiometabolic Forum

@theCMforum · X

The latest research by Wharton, et al. evaluated the efficacy and safety of orforglipron in adults with obesity, or who were overweight with at least one weight-related coexisting condition, and without T2D. Get all the key insights over on the #CMF today: https://t.co/2ENPRwPnir

TF

The Cardiometabolic Forum

@theCMforum · X

Want to learn more about the daily oral GLP-1 receptor agonist #orforglipron for adults with obesity? Head on over to the #CMF today and get all the insights from the latest publication by Wharton, et al: https://t.co/2ENPRwPnir https://t.co/DYG1hVXgYS

TF

The Cardiometabolic Forum

@theCMforum · X

We’ve just updated our detailed slide decks; this month includes the latest publication by Wharton, et al on #orforglipron for adults with #obesity. Head on over to the #CMF for free to access key publications in the world of cardiometabolic therapy: https://t.co/2ENPRwPV7Z https://t.co/IhHIv1L6Uc

FP

Food&Pharma

@rengerwitkamp · X

Farma juicht, voeding siddert en aandelen worden herbelegd. De nieuwe oraal toe te passen GLP-1 agonisten en krachtige Triple–Hormone-Receptor agonisten komen eraan. Zullen we ze maar gewoon toevoegen aan het drinkwater of toch gaan nadenken ? NEJM https://t.co/F2Bk3xcIQm

AG

arancha garcia

@arancha93845975 · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM

S

Shammari

@Shimri17 · X

RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…

南公

南江堂 洋書部【公式】

@Nankodo_Intl · X

【#NEJM日本国内版オンライン】 ★2023年9月に最も読まれた記事は⇒ 第1位　肥満成人に対する GLP-1 受容体作動薬オルフォルグリプロンの連日経口投与 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity S. Wharton and Others 日本語アブストラクト https://t.co/uF5OLRQV0D

BM

Benjamin Vipler, MD, MEd

@VipsMDMEd · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/boAOeoFyZQ

SM

Samar Hafida,MD

@Samarhafida · X

RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…

D

DovcK

@DovcK · X

RT @DrBobGabbay: A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to…

DB

Dr. Bob

@DrBobGabbay · X

A study on a new ORAL GLP-1 with 9.4% to 14.7% weight loss. The pace of innovation is dramatic providing more options to treat obesity. @AmDiabetesAssn @ADA_DiabetesPro #obesity #GLP1 https://t.co/kRS9XRGUiw

MS

Manolis Sinakos

@MSinakos · X

RT @eemh_hasl: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/u28mUshAO3

H

HASL

@eemh_hasl · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/u28mUshAO3

TT

Tom Tobin

@HedgeyeHC · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/AWtILpfOcw

SS

Sociedad SEEN

@sociedadSEEN · X

Estudio comentado por el Dr. Ignacio Llorente Gómez de Segura

DA

Dr Mushtaq Ahmad

@center_weight · X

RT @ObesitySeen:

JA

Juan Ignacio Arano

@AranoIgnacio · X

RT @ObesitySeen:

XB

Xavier Bayona

@XBayona · X

RT @XBayona:

NV

NURIA VILARRASA

@NURIAVILARRASA2 · X

RT @ObesitySeen:

C

Capita

@standard_capita · X

RT @Xiaoliu000928: Small molecule oral GLP-1 aolgonist. Lilly's realm where their rivals have lost their power? Daily Oral GLP-1 Receptor A…

오

오시아

@Xiaoliu000928 · X

Small molecule oral GLP-1 aolgonist. Lilly's realm where their rivals have lost their power? Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/HfO2TJr9bO

PM

Prof Brigadier Mamun Mostafi

@Prof_MMostafi · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/WQsZT39qan

MM

2 Minute Medicine®

@2minmed · X

RT @2minmed: #VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity #StudyGraphics #obesity https://t.co/…

KF

Kyle Swanson, MD, FAANS, FCNS

@kiswanson.medsky.network · Bluesky

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home

MM

2 Minute Medicine®

@2minmed · X

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity #StudyGraphics #obesity https://t.co/WzSBa63d3F https://t.co/e16hxZQs1D

DP

Dr. Vasista Palnati

@TheGutFeels · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

DP

Dr Ramdas Pananthattil

@PananthattilR · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DD

Dr Ashok Dalal

@DrAshokGastro · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

MG

Manuel Gracián

@ManuelGracian · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/oCiD1VdPAi

RG

Roberto Gutiérrez

@DrRobertoGuti · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

C

carly

@carly4330 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

L

Linda

@wordfinga · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

ER

erika lucia rosales

@erlurole · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

BB

Ben Wang, PharmD, BCCP

@BenWangPharmD · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/5b7uFrPuex

JO

Jaime Orfila

@jaime_orfila · X

Se van consolidando las evidencias q recomiendan el control farmacológico de la obesidad Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/2bjeyFUDNJ

TL

Tu pediatra Pro Lactancia

@MaryTuPediatra · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

SA

Sultan Aleesi

@sultanaleesi · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/mpV4UsLqEg

JF

Jonathan G. Stine, MD MSc, FACP

@JonathanStineMD · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

LH

Lukas Hatscher

@LukasHats · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

GW

Geoff Wong

@DrGeoffWong · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

HH

Hematology Media Center (HMC)

@US_HMC · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

دا

د زكريا الصفران

@doctorsafranzak · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJMالتوصيات العلمية الجديده تقر استخدام الادوية لتخفيف الوزن https://t.co/wZuGIZ5ISr

MS

Michael Schweitzer

@maschweitzer · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

EG

Esteban Jódar Gimeno

@estebanjodar · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

MG

Marcus Goncalves

@MarcusDGon · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/rv5Y0e6T9V

MP

Morin Marie-Philippe

@MorinMariePhil1 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DE

Dr. Gilberto Pérez López MD PhD ┃Endocrinólogo

@AndroMetabolic · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

GN

Giuseppe novelli

@NovelliGnovelli · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

PF

Philippe Froguel

@philippefroguel · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

JM

Jose Marquez

@JoseMarquezCard · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

KE

Kathrin Eller

@EllerKathrin · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

NS

Novi Yanti Sari

@slumberbell · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

IK

Irfan Khan, MB BCh BAO, MSc., BSc. Kin

@IrfuIKUCC · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

AM

Arsene Mekinian

@mekinian2 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

RF

Ricardo Fuentes

@rfanest · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DP

Dr. Gilberto Pérez López MD PhD

@Endocrino_PED · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

NX

Najia X.

@najaxth · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

B

Bookdasa

@Totoro19514032 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

D

DiabetoPitie

@DiabetoPitie · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

JM

Jorge Salazar M

@SalazarMJA · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

JN

Jaroslav Novotný

@novotnyjarosl · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

EC

ENDO-Clínica

@RAMIROBALDERAS1 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

E

endocatracha

@endocatracha · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

EP

Edgard Pais

@Edgard_2015 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/4mSvLcc9J2

PF

Pawan Rao MD, FASN

@nephronus · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

S

Sol

@ArualSogar · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

FZ

fausto heredia z.

@drfherediaz · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DR

Dr. Nazifa Kadery, PharmD, RPh

@dose_of_naz · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

A江

Associate Prof William KF Kong 江国辉副教授

@WilliamKokFaiK1 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

JA

Jose Carlos Arevalo

@joscarlor2 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

EJ

EOLO MORANDI JR.

@eolojr · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DB

Diego Bellido

@DiegoBellido2 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

MD

Ms Davis

@fangpusskins · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

IM

Ike Kendra Bolakale-Rufai, MD, MS

@Ike_Rufai · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

RM

Reuben Elovitz MD

@Concierge__MD · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

MM

Manuel Méndez

@mendez_bailon · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

HS

Hashem el- Serag

@SeragHashem · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

FM

Feisal D. Kahie, MD

@DrHabeysane · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

VC

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

み

みやび

@pazigid · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

OM

Osman Perdomo MD ?? ? ♻️

@osmanpv · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

CM

Cristobal Morales

@CristobMorales · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

Y

yuio

@kaihuahu1844631 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DS

Dr. Sou

@SwissHeartDoc · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

MM

Michelle Moore

@Michell30959835 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

K

Kai

@KaiMetaX · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

PN

Patricio Castro (#new?4???)

@pacastrom · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

S

SAEDYN

@SAEDYN_ · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

FS

Fundacion Camilo Salinas S⚡️

@CamiloSalinasOF · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

Sシ

syawal™ シ

@syawal · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

AM

Andrew J Sauer MD

@AndrewJSauer · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DA

Dr.Yasser Alwali

@DrYasserAlwali · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

EC

Ezeonufo Chukwunonso

@Ezeonufo · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

N

NEJM

@NEJM · X

Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists? https://t.co/gbnfDsdQOL https://t.co/Jj8BJEhDV2

TF

TM Smith, D.O. FAAEM

@RosenelliEM · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/0DJCGzijPC

KG

Kurikesh George

@Kurikesh · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

DV

Dr. Christian Velasquez

@drchvelasquezb · X

RT @florencarral: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ehY8GkyYlv

TC

Teresa Gijon Conde

@TGijonConde · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

HM

HUGO COLOMBO MD

@HCOLOMBO1958 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

AM

Adnan Safi, MD

@AdnanSaffi · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

S

SAEDYN

@SAEDYN_ · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM

H施

Harold Henrison C. Chiu, MD, FPCP, FPCEDM (施君明醫師)

@88DoubleDragon · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

陈진

陈美志..진미지

@FindingFirn · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc Editorial: Nex…

M

Molly20256

@Molly20186 · X

RT @GVlasuk: Impressive-Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/SzXT4zVgiO

C

CoinMuse

@coinmuse123 · X

肥満に対するGLP-1 Receptor Agonistの効果の論文が出たよ。 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ahMK69QDTc

KD

Kevin Davy

@davykevinp · X

Are we entering the Golden Age of obesity therapeutics? Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/Bw62MqW2We

GV

George Vlasuk

@GVlasuk · X

Impressive-Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/SzXT4zVgiO

CM

Chidambara .ML.

@chidambara09 · X

RT @DrSanjay277: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Great news for all the Obese people all over the gl…

VA

VICTOR AINEBYOONA

@victorAinebyona · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

DM

Dr.Sanjay MD

@DrSanjay277 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Great news for all the Obese people all over the globe ? @NEJM #MedTwitter #MedX #Meded #Foamed https://t.co/eSbSpVQ5kd

CD

CLINICAL TRIAL OF THE DAY

@mdwrtcom · X

Six months of @EliLillyandCo once daily oral orforglipron allowed to achieve up to 13% weight reduction in adult #obesity patients https://t.co/rWjbyjpga3 #VisualAbstract #endocrinology https://t.co/tx50P6awSs

HF

Hamdi Frikha

@frikha_hamdi · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

DM

Dr.Lama Amer, MD??

@Dr_Lama_Amer · X

“Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity” https://t.co/mdFjtPZgaP https://t.co/G5pZ9nsU8Z

GM

Glenn Loomis, MD

@GlennLoomisMD · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

VC

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

NH

Nada Hassib

@NadaHassib1 · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

JB

John P Erwin III MD MBA MACC (#BigPoppy )

@HeartOTXHeartMD · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

Z

zipjet

@zipjet · X

RT @CMichaelGibson: Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the or…

CM

C. Michael Gibson MD

@CMichaelGibson · X

Daily oral GLP-1 receptor agonist #Orforglipron for adults with obesity reduced weight by −8.6% to −12.6% across the orforglipron doses by 26 weeks. This is a daily oral drug rather than a weekly injectable cohortshttps://www.nejm.org/doi/full/10.1056/NEJMoa2302392

Tで

Tom Hsiung ???????‍⚕️ですね??！? ?

@TomHsiung · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/e7wd0MiVNe

SC

SEMERGEN_CV

@SEMERGEN_CV · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

PM

Paloma Moreno Moreno

@PalomaMorenoMo3 · X

RT @florencarral: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ehY8GkyYlv

AM

Ahmed Bennis MD ?

@drbennisahmed · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar https://t.co/PKKVtrcHkS

AA

Alexis A.

@Alexis_arbra · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

UH

Unidad de Riesgo Vascular HUJaen

@URiesgoV_HUJaen · X

RT @gomezdelgadoFJ: ? Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ?? ▶️ Ensayo fase II ??? ▶️ Sobrepeso y ob…

S

SAEDYN

@SAEDYN_ · X

RT @florencarral: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ehY8GkyYlv

AM

Alba Andreu Martí

@AlbaAndreuDN · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

SS

SEMERGEN | #SEMERGEN26

@SEMERGENap · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

FS

Fatima Villafañe Sanz

@FatimaVillaf · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

GE

Gt.HTA y ECVSEMERGEN

@gt_hta · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

GS

GT Diabetes Semergen

@SemergenGTDM · X

RT @vic_pallares: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGT…

VP

Vicente Pallares

@vic_pallares · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM ?https://t.co/hqLWEHMAhA @gt_hta @SemergenGTDM @SEMERGENap

FC

Florentino Carral

@florencarral · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ehY8GkyYlv

AR

Arshad Rashid

@arshadkema · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/dxPdNYBDJ3

A

andres

@palacioendocrin · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/wvQfdck1X7

MM

Matthew Martin, MD, FACS, McRIB

@docmartin22 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/76fDkb3oxr

F

FJGomezDelgado

@gomezdelgadoFJ · X

? Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ?? ▶️ Ensayo fase II ??? ▶️ Sobrepeso y obesidad ?⚖️ ▶️⬇️ #peso ⚖️ -9,4% ↔️-14,7% ▶️ > 50% ? consiguen ⬇️ 10% peso total ✅ @URiesgoV_HUJaen @Diabetes_SEMI @NEJM @sea_es @SAHTA_Sociedad https://t.co/RMY4VL5mhf

BZ

Boback Ziaeian ??‍♂️

@boback · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ⁦@NEJM⁩ https://t.co/H2TXb6j8Ap

NM

Neil Floch MD

@NeilFlochMD · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

A

Ady

@adychuela · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

MJ

Mª José Jiménez.

@MJJEndocrino · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

DT

Doc Gerry Tan

@docgerrytan · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

HH

Hyemin Huh

@Hyemin_Analyst · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

G

george

@drjorgehv · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

MM

Mouhand Mohamed, MD, MSc

@MouhandMD · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

DM

Dr.Lama Amer, MD

@Dr_Lama_Amer · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

HE

Haitham ElMaleh

@hmalmaleh · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

RC

Rima C.

@Rimachaka · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

LF

Luisma Flores

@deepgreen970 · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

RZ

R Giovanni Diaz-Zavala

@DrGiovanniD · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

DF

Dr.FernandoRuiz

@Ferruita · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

DJ

Dr. Shashank Joshi

@AskDrShashank · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

EJ

Ellie Jones

@_ELLIE_JONES_x · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

FF

Frantz Fanon

@waweru · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

JA

Juan Ignacio Arano

@AranoIgnacio · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

S

SSG

@jambukam8511 · X

RT @scottisaacsmd: Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events…

SI

Scott Isaacs

@scottisaacsmd · X

Oral #orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with −9.4% to −14.7% weight loss. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. https://t.co/vyuRxEJa3R https://t.co/itipwMohSH

LF

Lisal Folsom

@DocFolsom · X

Weight loss effects with oral orforglipron - funny name, legit results. #GLP1 #weightloss #science @NEJM https://t.co/DEfBoqkUvq

D糖

Dr.U@糖尿病メモ

@dr_ukio · X

すみません、オルフォグリフロン(空腹制限なし経口GLP-1) 肥満症への第2相試験のリンク【NEJM】が抜けていました 272名、平均BMI38、36週後オルフォ群最大量で-15%減量。オルフォ群で10-17%に投与中止につながる有害事象あり。 https://t.co/AwxdPWN6OR https://t.co/R1yuQq4h0F

AM

Antonio Manteca

@amango30 · X

RT @RevistaMFSamfyc: El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564

RM

Revista MFAndalucia

@RevistaMFSamfyc · X

RT @RevistaMFSamfyc: El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564

RM

Revista MFAndalucia

@RevistaMFSamfyc · X

El agonista oral diario de GLP-1 orforglipron para adultos con obesidad https://t.co/gVpxtUjUTF PMID 37351564

SS

Sociedad Española de Patología Digestiva (SEPD)

@sepdigestiva · X

RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…

S

Simon

@oncopharmacist · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/K97eC3ZPBW

LM

Laporte Anne-Marie

@LaporteAnneMar2 · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

JC

Joaquin Cabezas

@JCabezasGlez · X

RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…

EO

Elena del Olmo

@eledelolmo · X

RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…

X

Xime

@ximenita_ale · X

RT @DrJavierCrespo: Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelent…

JC

Javier Crespo

@DrJavierCrespo · X

Un nuevo actor en el tratamiento de la obesidad (y, quizás en un futuro inmediato en el tratamiento del #SLD). Excelentes resultados (no tan espectaculares como con Retatrutide), que nos acercan a un tratamiento a la carta de la obesidad. @sepdigestiva https://t.co/lJEuSYaBBT

MS

Michael Schweitzer

@maschweitzer · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

JN

Jaroslav Novotný

@novotnyjarosl · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

JK

Joshua Kimbrell

@joshkimbre · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

AL

Adam Leventhal

@AdamMLeventhal · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

HG

Henry Gaviria

@henrygav5 · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

SA

Sultan Ahmed

@sultan__ahmd · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

JA

José Alberto

@josealberto_gc · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

C

Clopidoken

@clopidoken · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

PM

Pub Health Monitor

@monitor_PH · X

RT @NEJM: 3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/…

N

NEJM

@NEJM · X

3. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #gastroenterology https://t.co/NslyhAAxIJ

D糖

Dr.U@糖尿病メモ

@dr_ukio · X

■ADAのまとめメモ オルフォグリフロン(空腹制限なし経口GLP-1) 第2相試験 for 肥満,【NEJM】のリンクが抜けていました。スミマセン。 平均BMI38の272名、36週後の体重変化はオルフォ群で-9.4～-14.7％。オルフォ群の10-17%に投与中止につながる消化管症状。 https://t.co/AwxdPWN6OR https://t.co/P1wy8V5org

JC

Javier Crespo

@DrJavierCrespo · X

@sepdigestiva @AEEHLiver @NEJM @DigValdecilla In a little while, I will remind you of two more studies that have a disruptive impact on our approach to obesity treatment; 1) Triple-Hormone-Receptor AgonistRetatrutide for Obesity - A Phase 2 Trial and 2) Daily Oral GLP-1 Receptor Agonist-Orforglipron for Adults with Obesity

SP

Silvia Pellitero

@PelliteroSilvia · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

SA

Sharona Azriel

@SharonaAzriel · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

O

ObesitySEEN

@ObesitySeen · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

MV

Marta Varas❣️

@VarasMayoral · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/VXxiSkk42S

PB

Polar Bear ?

@chaiwat_non · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

DA

Dr Mushtaq Ahmad

@center_weight · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

MY

María Ballesteros #yoelijoEndocrino

@mdballesteros · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

JA

Juan Ignacio Arano

@AranoIgnacio · X

RT @ObesitySeen: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

O

ObesitySEEN

@ObesitySeen · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/nSx57dA9sg

L

lovely

@geraniumlove · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

GM

Giuseppe Maltese

@docmaltese · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/LI7Rhs4guG

M

mamylona

@mamylona1 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

P食

Pon｜食と健康

@PonNutr · X

GLP-1作動薬オルフォルグリプロンの経口投与ダイエットのRCT論文（NEJM） ✅有意な体重減少あり ✅有害事象は、注射のGLP-1 受容体アゴニストの報告と同程度 https://t.co/ThXxYKrSy4

P

pinacol

@pinacol · X

【RCT】糖尿病でない肥満または体重関連の共存条件を1つ以上もつ過体重成人へのOrforglipronの投与は、プラセボの投与と比較して、体重を減少させた。 #ペ読 https://t.co/0A37r3PLkA

グ

グリニア

@fantasticvoyag5 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/0xDIgDj9Ez

MA

Mauricio Ambriz

@AmbrizMau · X

En este estudio fase 2, el ORFORGLIPRON oral diario, un agonista del receptor de GLP-1 no peptídico, se asoció con la reducción de peso. Los eventos adversos fueron similares a los de los agonistas del receptor de GLP-1 inyectables. N Engl J Med 2023; DOI: 10.1056/NEJMoa2302392 https://t.co/qt4QjKijvS

MS

Miriam Sandín

@miriamsandin · X

RT @AbeytuaManuel: ORAL #GLP-1 ORFORGLIPRON FOR #OBESITY.- DOI:10.1056/NEJMoa2302392 NEJM June,23/2023 Fueron randomizados 272 #obesosnodia…

AP

Ana Peinado

@AnaPeinadoCard · X

RT @AbeytuaManuel: ORAL #GLP-1 ORFORGLIPRON FOR #OBESITY.- DOI:10.1056/NEJMoa2302392 NEJM June,23/2023 Fueron randomizados 272 #obesosnodia…

猫

猫になりたい薬剤師

@Vannyamoto · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/IAto8bZSRi イーライリリーすごいわ ニーズとマーケティング戦略に唸る

MP

Morin Marie-Philippe

@MorinMariePhil1 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

T

theunretired

@theunretired · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/jc16pwUWpD

MT

Martín López de la Torre

@elendocrino · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

RD

redGDPS Diabetes

@redGDPS · X

Full text links @NEJM Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/1E9FUwJy5T

RD

redGDPS Diabetes

@redGDPS · X

Acceso en @PubMedOnline https://t.co/x1ONaKypO7

'Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists.' https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home

SL

silex知の文献サービス (Silex Press LLC.)

@silex_transl · X

#Lilly の #経口GLP1Rアゴニスト薬 #orforglipron がP2で抗肥満効果を示す。効果も安全性も注射薬と同等、と。承認は確実。出現中巨大 #減量薬市場 のリーダーはLillyに。 ttps://www.nejm.org/doi/full/10.1056/NEJMoa2302392

AW

Andy_Weeble_Weaver

@AndrewW66619812 · X

The paper on 'Orforglipron' in "NEJM" the above "Nature" article is partly based upon, & links to: “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity” 2/3 https://t.co/l4LqwHJaK8

V

Vivanna

@DocVivanna · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity NEJM https://t.co/XbvZwUaKx0

RB

Robert Belvís

@robertbelvis · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

AB

Angie van Bemden

@DrvanBemden · X

Daily Oral GLP-1 Receptor Agonist #Orforglipron for Adults with #Obesity | #NEJM https://t.co/saPkWcwPzT

CD

Cindi Larimer, M.D.

@GMOSclinic · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

D

Diabetologistnote

@n_ishizuka · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/0KeLYYMC0z

MB

Myriam Beaulieu

@DraMyriambo10 · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

T

Truclamnguyen

@truclamnguyen · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

しバ

しゅー?バイオx米国株

@SU_pharma · X

$LLY 経口GLP-1RAのOrforglipronは強い体重低下を示し、経口GLP-1のbest in classへ前進。 肥満のPh2試験はNEJMに掲載? ADAでも盛り上がってるようです。 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/M7EeHkEplo

ND

Nathalia Romanelli V. Dragano

@NathDragano · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JR

José Antonio Rubio

@jarubiogarcia · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/YLRJn3WTp1

MA

Mohammed Alhazmi

@hazmad123 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JK

Johannes Krieg

@johannes_krieg · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

DM

Diego Anazco, MD

@danazcomd · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

VE

Veronica Espinosa

@spin1371 · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

み

みやび

@pazigid · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JL

Jose Daniel Mosquera Lozano

@jdmosqueral · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

KA

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM

@KOBPharmD · X

RT @Samarhafida: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/j43qx4VRVu

M

Molly20256

@Molly20186 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

WM

W. Scott Butsch, MD MSc

@drbutsch · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

SM

Samar Hafida,MD

@Samarhafida · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/j43qx4VRVu

BD

Basem Mishriky, MD, FACP, ABOM Diplomate

@BasemMishriky · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

ME

Miguel A. Maria. Medico de Familia. #embajadorSEEN

@Miguel_A_Maria · X

RT @ana_apiecar: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/kujwpwpLLZ @SociedadSeedo @SEM…

DC

Daniel Coyne

@DrDanMO · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/yXlpInpi07

JV

Jan Verwerft

@VerwerftJan · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

A

Abstream

@abstreamme · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity #science #publication #research #publications https://t.co/yObjSekFji

AS

Abduvalieva Sagynbu

@ASagynbu · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

MA

Manuel Abeytua

@AbeytuaManuel · X

ORAL #GLP-1 ORFORGLIPRON FOR #OBESITY.- DOI:10.1056/NEJMoa2302392 NEJM June,23/2023 Fueron randomizados 272 #obesosnodiabéticos, a recibir una de cuatro dosis de orforglipron vs placebo durante 36 semanas. Con orforglipron perdieron 9,4%-14,7% de su peso y con placebo, el 2,3%. https://t.co/qtiNA5FFfW

SG

Simon Geerts

@s_geerts · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

PM

Pati M

@PatiM2 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

AF

Alex Kharlamov MD FESC FACC FEACVI FAHA ????

@drskharlamov · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

MN

Marcia S Newman

@marciasgreen · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

VC

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

L

Linda

@wordfinga · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

H

hlhwu

@hhlwu · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

김K

김정한 Jeong Han Kim

@DrJHK · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

青

青島周一

@syuichiao89 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

冷

冷たいお水を探すハイジ

@asdfghjkliuyqe · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JA

Juan Ignacio Arano

@AranoIgnacio · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

ML

Makoto Kodaira | LeMon ✨

@makotokodaira · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

DY

Dra. Erica Yama

@Ericayamitayama · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

EC

Ezeonufo Chukwunonso

@Ezeonufo · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

EJ

Ellie Jones ?

@_ELLIE_JONES_x · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

JB

Joshuan J. Barboza

@joshuanbarbozam · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

DL

Dr. Raúl Zenteno Langle

@DrZentenoLangle · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

CM

Carlos Maiorana

@MaioranaCarlos · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

MA

Mazin Almaghrabi

@MazinAlmaghrabi · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

GP

Grigorios (Greg) Panagiotou

@gr_panayio · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

DE

Dr. Hugo Corrales - Endocrinología.

@hugoendocrino · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

TK

Ted Kyle

@ConscienHealth · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

XJ

Xaviar Michael Jones

@XMichaelJonesMD · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

EG

Esteban Jódar Gimeno

@estebanjodar · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JM

Julio Mayol

@juliomayol · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

MP

Manuel Sánchez-Prieto

@snchez_manu · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JL

Jen Li

@JLi_Renal · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

LT

Lorenzo Tucci

@DocTux92 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

VS

Varun Sharma

@VarunSharmaNHS · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

MS

Marcelo Santos

@ProfDrMarcelo · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

LE

L' Extatique_75

@ExtatiqueL · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

LM

Laporte Anne-Marie

@LaporteAnneMar2 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

UE

UW Endocrinology

@UWEndocrinology · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

JH

Jose Hernandez

@Pharma_Mty · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

VG

Venkata Srikanth Garikipati

@GarikipatiSrik2 · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

DG

Dr. Martha Gulati ♥️?❤️‍???

@DrMarthaGulati · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

LP

Lebogang Phahladira ??

@phahlax · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

PM

Pub Health Monitor

@monitor_PH · X

RT @NEJM: Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https…

N

NEJM

@NEJM · X

Original Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/lNjqjAF5oc #ADA2023 https://t.co/4kvka2Zwo1

Mع

Moutaz Osman معتز عثمان

@osman_moutaz · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

RM

Ritwika Mallik

@Ritwika_mallik · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/G33yalmcBm

B

bdp290

@bdp290 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

AC

ajiteshkadam17@gmail.com

@ajiteshkadam17 · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

SD

Samir C. Grover, M.D.

@Samir_Grover · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

SG

Steve Greene

@SJGreene_md · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

AM

Alfredo Mendoza

@A_Mend_Calvillo · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

KY

Kevin Yau

@KevinYauMD · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

M

maldinilin

@maldinilin · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

JW

Jamie Wang

@jamiewang1228 · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

TH

The Heart

@ZHeart11768530 · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

J

Juanmarcosgg

@juanmarcosgg · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

AG

Andy Grannell

@Grannell_ · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

CM

Carlos Morillas

@61Morillas · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

KE

Kim Eunho

@PeraVich · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

PL

Philipp Lopatka

@LopatkaPhilipp · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

SM

Seba GZ, MD, MSc

@sebagz1 · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

HB

Hooman Bakhshi

@BakhshiHooman · X

RT @mividovich: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity - weight down... - HBA1C down... Bonus - LDL do…

FV

Francois Venter

@FrancoisVenter3 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

MV

Mladen Vidovich

@mividovich · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity - weight down... - HBA1C down... Bonus - LDL down... - BP down... https://t.co/kZpT8fWXZg https://t.co/XbZjcxrsnI

MJ

Marisa de Jesus

@dra_MDeJesus · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/ySpgDAKXdt

JN

Jeffery Nutrition

@JefferyNutr · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

AK

Amira Al Kharusi

@amira_alkharusi · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

O

ObesitySEEN

@ObesitySeen · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

PS

Pablo Matías Soler

@Pablomatsol · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

GS

GT-SEMI Diabetes, Obesidad y Nutrición #17DM_SEMI

@Diabetes_SEMI · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

TK

Ted Kyle

@ConscienHealth · X

RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…

MG

M. Shaan Goonoo ??????

@MGoonoo · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

E

EASDelearning

@EASDelearning · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

PB

Polar Bear ?

@chaiwat_non · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

PB

Polar Bear ?

@chaiwat_non · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

LL

Leicester Real World Evidence (LRWE)

@LRWEUnit · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

海

海が好きなネコ

@C903IWApiwbTNjU · X

「肥満成人向けの毎日の経口GLP-1受容体作動薬オルフォルグリプロン」 https://t.co/aigj8CldIa

JM

José Jesús Broseta Monzó

@jbroseta · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

JW

Jamie Wang

@jamiewang1228 · X

RT @ValleAlfonso: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI w…

AV

Alfonso Valle

@ValleAlfonso · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ? 272 nonDM, mean body weight was 108.7 kg, BMI was 37.9 ⏰ week 26 ?mean change from baseline in body weight ranged from −8.6% to −12.6% across the orforglipron dose cohorts −2.0% in the placebo group ? discontinuation of orforglipron in 10 to 17% of ? @NEJM ?https://t.co/1s1i21qRBM

SW

Simon Williams ???????

@DrSRPWilliams · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

DP

Dr. Swapneil Parikh

@swapneilparikh · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

DP

Dimitris Papamargaritis

@ri_tis · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

JA

JoseM Garcia Almeida

@jgarciaalmeida · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

TB

Tere Barenys

@tereheda · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

EM

Edoardo Melilli

@EdoardoMelilli · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

DP

Dr Jorge Rico Fontalvo. MD.FISN. FSLANH , PhD

@jorgericof · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

ME

Mohgah Elsheikh

@DrMohgah · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

CC

Christian Calderón

@Christi79059992 · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

BD

Basem Mishriky, MD, FACP, ABOM Diplomate

@BasemMishriky · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

FR

Fahad Razak

@DrFahadRazak · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

NM

Neil Floch MD

@NeilFlochMD · X

RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…

KF

Kevin Fernando

@drkevinfernando · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

SA

Sharona Azriel

@SharonaAzriel · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

IP

Ian Patton, PHD

@IanPatton55 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

JC

Jon Cunningham

@JonWCunningham · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

DF

Dr.FernandoRuiz

@Ferruita · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

DM

Dr.Roberto Collazo-Maldonado

@collazor1 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

MV

Muthu Vaduganathan

@mvaduganathan · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

DB

Diego Bellido

@DiegoBellido2 · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

N

Norestense

@Rooney73029223 · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

PH

Patrick Holmes

@drpatrickholmes · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

DC

Dr. Zoobia W. Chaudhry?

@zoobiachaudhry · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

EZ

Evan Zeitler

@LittleBigGloms · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

JW

Jamie Wang

@jamiewang1228 · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

JW

Jamie Wang

@jamiewang1228 · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

T

Tom

@youareinformed · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/RYrrUl8oWs

SD

Summer the Dietitian

@SummerDietitian · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

AS

Abdalellah Sami

@AbdalellahSami · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

MM

Michael Albert, MD

@MichaelAlbertMD · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

VD

Viri diana

@viridiana_dlt · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

VD

Viri diana

@viridiana_dlt · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

KF

Kevin Fernando

@drkevinfernando · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

SM

Samar Hafida,MD

@Samarhafida · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

HF

Hamdi Frikha

@frikha_hamdi · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

SM

Samar Hafida,MD

@Samarhafida · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

PC

Pratik Choudhary

@drpratikc · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

JA

Juan Ignacio Arano

@AranoIgnacio · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

SM

Samar Hafida,MD

@Samarhafida · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

JL

Julie A. Lovshin

@JulieALovshin · X

RT @seanwharton: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a…

UA

Umaira Aziz

@documi · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

SW

sean wharton

@seanwharton · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a significant advancement in medicine. This will improve access to care. #ada2023 https://t.co/ChwqtRQeMn

FZ

fausto heredia z.

@drfherediaz · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

RM

Rodolfo J. Galindo MD

@RodolfoJGalindo · X

RT @CristobMorales: https://t.co/4MowDndrNz Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week…

CM

Cristobal Morales

@CristobMorales · X

https://t.co/sPd3h5ApiR Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity @NEJM #ADA2023 “At week 36, the mean change ranged from −9.4% to −14.7% with orforglipron” @SociedadSeedo @SEDiabetes @LillyTrials @Vithas @RodolfoJGalindo @estebanjodar @irenecabmat @albertlecube @DrTinahones @DiegoBellido2

AS

Ana Piera #JuntosEsMasFacil??? #StopInercia?

@ana_apiecar · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/kujwpwpLLZ @SociedadSeedo @SEMERGENap @SADENO_ @primastcar

MF

Manuel Codas, MD, FACP ®

@ManucoMd · X

RT @GoggleDocs: #ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti…

G

GoggleDocs

@GoggleDocs · X

#ADA2023 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM @ADA_DiabetesPro @kamleshkhunti https://t.co/2S38NygnAZ https://t.co/fjNEbr1ift

RR

Raquel Rozdolski

@RaquelRozdolski · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://t.co/b09Ae5tSkS

AF

Alberto Dias Filho

@albertodiasf · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/l03xmZCmUQ

名

名前

@akkiii0830 · X

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM https://t.co/vlvGKJGoJ5

S

Solveig

@solveigsig · X

RT @ConscienHealth: Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accru…

TK

Ted Kyle

@ConscienHealth · X

Early data on new incretins leads us to think therapeutic options for #obesity will be growing with real benefits accruing to people living with the disease. Free access to the @NEJM publication on #orfoglipron available here. #ADA2023 #ADARME https://t.co/JWH0YFLDVh https://t.co/XzmOmsdLMi

N

Get the Foundayo Pill for Weight Loss – Online Prescription

News

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | New England Journal of Medicine, Accessed March 2026. Eli Lilly and Company. What ...

N

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

News

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. June 23, 2025. Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, led to ...

N

GLP-1 single, dual, and triple receptor agonists for treating type 2 ...

News

Blevins, L. Connery, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med, 389 (10) ...

N

StanfordMed Matters: GLP-1 Agonists for Obesity

News

https://doi.org/10.1056/NEJMoa2302392. For activity related questions, please contact. Name: Alisa Richardson Title: Education Program Manager Email: alisar ...

N

GLP‑1 Medications - The Actuary Magazine

News

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2302392;Pearson, S. D., Whaley, C. M., & Emond, S. K. Affordable access to GLP‑1 obesity medications: Strategies ...

N

Orforglipron, an Oral Small-Molecule GLP-1... - Ovid

News

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity · Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes · GLP-1 Receptor ...

N

Effects of once-daily oral orforglipron on weight and metabolic markers

News

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-88. doi: 10.1056/NEJMoa2302392. » https://doi.org/10.1056 ...

10.1056/NEJMoa2302392. Contributors: Sean Wharton; Thomas Blevins; Lisa Connery; Julio Rosenstock; Sohini Raha; Rong Liu; Xiaosu Ma; Kieren J. Mather; Axel ...

N

A New Era in the Medical Management of Obesity - Annual Reviews

News

389(10):877–8810.1056/NEJMoa2302392. [Crossref] [Google Scholar]. 79. Buckeridge C, Cobain S, Bays HE, et al. 2025. Efficacy and safety of danuglipron (PF ...

N

GLP-1-based medications: Mechanisms involved in obesity treatment

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med, 389 (2023), pp. 877-888. https://dx.doi.org/10.1056/nejmoa2302392 | ...

doi: 10.1056/NEJMoa2302392. Pubmed Abstract · CrossRef · Google Scholar. 21. FriasJPHsiaSEydeSLiuRMaXKonigMet al. Efficacy and safety of oral orforglipron in ...

N

GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment ...

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med., 389 (2023), pp. 877-888. https://dx.doi.org/10.1056/NEJMoa2302392 | ...

(https://www.nejm.org/doi/10.1056/NEJMoa2302392). 2018. A Study of Orforglipron (LY3502970) in Adult Participants with. Obesity or Overweight With Weight ...

doi:10.1056/NEJMoa2302392. DOI: 10.1002/doi2.67. Diabetes Obes Metab. 2023;1:e67. wileyonlinelibrary.com/journal/doi2. © 2023 John Wiley & Sons Ltd. 1 of 1.

doi:10.1056/NEJMoa2302392. Rosenstock J, et al. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056/NEJMoa2505669. International Conference on Harmonisation ...

F

Faisal Shakir (@drfaisalshakir) - Facebook

Facebook

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Obesity is a major risk factor for many leading caus... Sarfaraz Niazi and 2 ...

N

Management of Type 2 Diabetes Mellitus With Noninsulin ... - AAFP

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. 45.Frias JP, Hsia S, Eyde S, et al. Efficacy and ...

N

New Obesity Drugs: Latest Pipeline and Research - WebMD

News

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity," "Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.

N

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

News

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. byWinnie Liu · September 13, 2023. in StudyGraphics.

Y

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

YouTube

NEJM: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

F

Orforglipron shows weight loss benefits for both menopause and ...

Facebook

15150 [747] doi:10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26) ...

T

ue cada pequeño hábito cuenta. Hegel 153 Consultorio ... - TikTok

TikTok

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine, 389(10), 877–888 ...

F

Orforglipron es una de las nuevas alternativas que se estudian para ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Orforglipron was linked to consistent weight loss in addition to ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

F

¿Una pastilla en vez de la inyección para bajar de peso ... - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

¿Te acaban de diagnosticar diabetes? Una pastilla, sin inyección El ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Una opción oral de GLP-1 se acerca a una pregunta clave - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

Y

Orforglipron: After the pen, can the pill maintain weight? | Masterclass

YouTube

... 10.1056/NEJMoa2302392 2. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England ...

I

Novidade no tratamento da obesidade: o GLP-1 oral. A inovação ...

Instagram

doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento médico ...

F

¿La pastilla GLP-1 se toma en ayunas? No. Así se usó ... - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Once-daily oral GLP-1 receptor agonist Helps reduce appetite and ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ ...

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development ...

N

Corbus Pharmaceuticals Announces Positive Topline Data from ...

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development ...

N

Corbus Pharmaceuticals Announces Positive Topline Data from ...

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development ...

N

Corbus Pharmaceuticals Announces Positive Topline Data from ...

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development ...

T

La ciencia avanza para hacer los tratamientos más accesibles y ...

TikTok

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Y

September 6, 2026 - YouTube

YouTube

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine, 389(10), 877–888 ...

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Orforglipron: un GLP-1 oral que promete cambiar el tratamiento de ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

I

O primeiro comprimido GLP-1 para obesidade foi aprovado nos ...

Instagram

doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento médico ...

N

Orforglipron News: Foundayo FDA Approved for Weight loss - GoodRx

News

Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. The New England Journal of Medicine. Wharton, S., et al. (2025) ...

Y

Why an Oral GLP-1 is So Hard to Build (MoA Breakdown) - YouTube

YouTube

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine, 389(10), 877–888. ⚠️ Medical ...

L

CagriSema Noninferior to Tirzepatide on Weight Loss in Type 2 ...

LinkedIn

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults With Obesity. NEJM. 2023;389(10):877-888. -American Diabetes Association ...

F

Once-weekly 9-mg mazdutide led to 17% mean weight loss vs 2 ...

Facebook

org/doi/full/10.1056/NEJMoa2411528 · No photo description available. Heinz Müller and 33 others. 34 reactions ·. 8 comments. ·. 2 shares. China ...

F

What are the effects of Orforglipron (FOUNDAYO) tablets on reactive ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

Connery, et al., “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults With Obesity,” New England Journal of Medicine 389, no. 10 (2023): ...

F

ORFORGLIPRON VS. WEGOVY®️ PILL Dos agonistas ... - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Orforglipron es un medicamento en investigación que ha generado ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

I

ORFORGLIP: A inovação em tratamento oral Conheça o ... - Instagram

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo ...

F

GLP-1: más allá del peso, empleo y pareja Un nuevo working paper ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

L

Orforglipron: GLP-1 Receptor Agonist for Weight Loss and Diabetes ...

LinkedIn

... 10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] doi ...

L

GLP-1 Candidate Shows 12.1% Weight Loss in Phase II Trial

LinkedIn

A phase II trial of an oral small-molecule GLP-1 candidate reported up to 12.1% body-weight reduction after 36 weeks in adults with obesity ...

N

HRS-7535, an oral small-molecule GLP-1 receptor agonist ... - Nature

News

et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877–888 (2023).

I

No injections. No needles. Just a pill. Orforglipron is an ... - Instagram

Instagram

... 10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] doi ...

L

Roberto H. Gonzalez's Post - LinkedIn

LinkedIn

The Food and Drug Administration (FDA) has approved Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron, for adults with ...

L

Activated Charcoal Combination Therapy for Primary Gout Efficacy ...

LinkedIn

... 10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] ...

Wharton, S ∙ Blevins, T ∙ Connery, L ∙ et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 ...

F

El fármaco oral elecoglipron logró mejorar el control glucémico y ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

In a phase 3 trial of Chinese adults with #obesity, mazdutide ...

Facebook

nejm https://www.nejm. org/doi/full/10.1056/NEJMoa2411528 · No photo description available. Heinz Müller and ...

F

In the ACHIEVE-5 randomized clinical trial, addition of oral ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

F

Once-weekly 9-mg mazdutide led to 17% mean weight loss vs 2 ...

Facebook

The image displays a screenshot of an article from nejm.org titled "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity".

F

Research Summary: Adding oral orforglipron to titrated insulin ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

L

Ascletis Presents Obesity Treatment Data at ADA 2026 Scientific ...

LinkedIn

... 10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi:10.1056/NEJMoa2511774 [750] doi:10.1016/S0140-6736(26)00202-3 [751] ...

I

o futuro dos agonistas GLP-1 agora em versão oral! O orforglipron é ...

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ ...

Y

It Might Beat the Peptides in a Key Way - YouTube

YouTube

... 10.1056/NEJMoa2302392. [Study 748] Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of food consumption on the ...

I

Uma nova era no tratamento da obesidade e do diabetes tipo 2 ...

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ ...

I

Novas perspectivas no tratamento da obesidade. ​Esta semana, o ...

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ ...

N

What is Foundayo? - Drugs.com

News

DOI: 10.1056/NEJMoa2302392; Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile ...

I

O orforglipron, desenvolvido pela Eli Lilly, é um agonista do GLP-1 ...

Instagram

doi:10.1056/NEJMoa2511774. Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389 ...

I

A Eli Lilly, mesmo laboratório por trás do Mounjaro ... - Instagram

Instagram

doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento médico ...

Y

GLP-1 Pills vs Shots: You Might Be Choosing Wrong - YouTube

YouTube

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity https://pubmed.ncbi.nlm.nih.gov/37351564/ Diabetes, Obesity and ...

N

How long does it take for Foundayo to work? - Drugs.com

News

https://doi.org/10.1056/NEJMoa2302392; Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla ...

N

FDA approves Foundayo, an oral GLP-1 alternative to Wegovy and ...

News

The Food and Drug Administration (FDA) has approved Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron, for adults with ...

I

Mais um GLP-1 chegou, mas dessa vez em comprimido ... - Instagram

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo ...

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo ...

F

¡Nueva Era en Farmacoterapia de la Obesidad! FDA Aprueba ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

I

Uma nova era no tratamento da obesidade pode estar ... - Instagram

Instagram

doi:10.1056/NEJMoa2511774. Wharton S, et al. Daily Oral GLP-1 ... doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo ...

F

ยา Orflorglipron ขนาดที่ได้รับ approved ใน US FDA คือ 2.5 mg, 5.5 mg ...

Facebook

Daily Oral GLP- 1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023; 10.1056/NEJMoa2302392. -คลังข้อมูลยา(Drug ...

I

GLP-1 dünyasında sessiz ama büyük bir kırılma yaşanıyor. Artık ...

Instagram

... 10.1056/NEJMoa2302392 https://diabetesjournals.org/care/article/46/9/1738/153251/Oral-Nonpeptide-GLP-1-Receptor-Agonists https://www.reuters ...

F

FDA aprueba Foundayo, primera pastilla GLP-1 para bajar de peso ...

Facebook

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen Marin Vega and 2 others. 3 reactions ·. 1 comment. GLP1 ...

Y

Orforglipron:NEW GLP-1 Pill Approved! (Obesity Doctor) - YouTube

YouTube

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. PMID: 37351564 S Wharton ...

I

Photo by Dra Monique Flores Zarath (@dramoniqueflores) - Instagram

Instagram

doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento médico ...

F

Radio Punto 7 Temuco - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

I

NOVIDADE QUE VAI MUDAR O JOGO NA OBESIDADE ... - Instagram

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo ...

I

a primeira pílula oral GLP-1 de molécula pequena que chega com ...

Instagram

2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento ...

L

INHALE-1 Study Results on Post-Meal Hyperglycemia Treatment ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Global Antithrombotic Stewardship Gains Momentum ... - LinkedIn

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Direct Oral Anticoagulants and Factor XI/FXIa Inhibition in ... - LinkedIn

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Thrombin Generation Testing Enhances Standard of Care with ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Timing is everything in oncology pharmacy | Ahmet Sami Bosnak ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Blood Collection Devices Market to Reach $13.02 Billion by 2030

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Domperidone Study Results: CIN-102's Effect on Cardiac ... - LinkedIn

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Anticoagulation Management Certifications for Pharmacists ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

F

People with type 2 diabetes had better blood sugar control and more ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

F

LA NUOVA PILLOLA ANTIOBESITA' (E ANTIDIABETICA) DI ELI ...

Facebook

nejm.org/doi/full/10.1056/NEJMoa2511774 N Engl J Med 2023;389:877-888 - https://www.nejm. org/doi/full/10.1056/NEJMoa2302392 · No photo ...

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

F

El fármaco oral orforglipron supera la eficacia de la semaglutida en ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Efficacy and safety of once-daily oral orforglipron compared with oral ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

I

A maior dificuldade no emagrecimento não é perder peso, é manter ...

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Previsão internacional estimada: 2025-2026. ORFORGLIPRON NÃO É ...

L

Eli Lilly's Orforglipron: Oral GLP-1 Alternative | AbbatiaLabs posted ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

Retatrutide is the latest weight loss medication that's currently in ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

FDA Removes Suicidal Ideation Warning from GLP-1 Receptor ...

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

L

#technicaluniversityofdenmark #dtu ... - LinkedIn

LinkedIn

2023;389:877–888 DOI: 10.1056/NEJMoa2302392 What makes it different? • Non-peptide small molecule • No need for absorption enhancers ...

I

Dr Ricardo Pacheco | Médico Nutrólogo | RQE 134452 - Instagram

Instagram

doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo educativo e informativo. Não substitui consulta, diagnóstico ou acompanhamento médico ...

N

Daniel J Drucker GLP 1 Based Therapies For Diabetes | PDF ...

News

obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2302392 (2023). Lancet ...

N

Semaglutide: GLP-1 RA For Diabetes and Obesity | PDF

News

10.1056/NEJMoa2302392. Epub 2023 Jun 23. PMID: 37351564. [6]http://www.newsthevoice.com/news/articleView.html?idxno=32782 [7]CagriSema and the link between ...

N

Effectiveness and Safety of Drugs For Obesity BMJ | PDF | Obesity ...

News

doi:10.1056/NEJMoa2302392 30. doi:10.1016/S0140-6736(23)01163-7 166 Saxena AR, Frias JP, Gorman DN, et al. Tolerability, safety and 176 Heymsfield SB ...

N

Jurnal | PDF | Lipoprotein | Low Density Lipoprotein

News

N Engl J Med 2023;389:877–88. of randomized controlled trials. Obes Surg 2019;29:964–74. https://doi.org/10.1007/ https://doi.org/10.1056/NEJMoa2302392

F

silex - サイレックス 知の文献サービス

Facebook

出現中巨大 #減量薬市場 のリーダーはLillyに。 ttps://www.nejm. org/doi/full/10.1056/NEJMoa2302392.

N

Comprehensive Obesity Management Review | PDF | Obesity | Leptin

News

10.1056/NEJMoa2302392. 44. Ji, L., Jiang, H., Cheng, Z., et al. (2023). A phase 2 randomised controlled trial of mazdutide in chinese overweight adults or ...

N

The Rise of Ozempic: How Surprise Discoveries and Lizard Venom ...

News

(https://www.nejm.org/doi/full/10.1056/NEJMoa2302392). Plenty of weight-loss drugs have failed, too. Anti-obesity drugs with other targets – such as those ...

N

glp nonpeptidic | PDF | Systematic Review | Glycated Hemoglobin

News

doi.org/10.1056/NEJMoa2302392. Writing - review & editing. Alexandra Klisic: Writing -original draft, [14] Cochrane Handbook for Systematic Reviews of ...

N

In 30 Jahren vom Geheimtipp zum Bestseller

News

DOI: Page 8. 3. Perspektiven der Diabetologie 2/2023 | Deutsches Ärzteblatt. 10.1056/NEJMoa2302392. Epub 23. Juni 2023. PMID: 37351564. 60. Davies MJ, Aroda VR ...

N

Erstmals ein wirksames Abnehmmedikament

News

N Engl J Med. 23 June 2023; DOI: 10.1056/NEJMoa2302392. 11. Brandt SJ, Müller TD, DiMarchi RD, et al.: Peptide-based multi-agonists: a new para- digm in ...

N

Orforglipron | PDF

News

DOI: 10.1056/NEJMoa2302392. You might also like. 41. PDF. No ratings yet. 41. 8 pages. Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To An ...

N

Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller ...

News

Erste Ergebnisse, dass GLP-1 eine diabetische Stoffwechsellage erheblich positiv beeinflussen kann, gab es bereits seit Dekaden.

F

Dr. Hozayen

Facebook

org/doi/full/10.1056/nejmoa1411892 - https://www.nejm. org/doi/full/10.1056/NEJMoa2301972 - https://www.nejm. org/doi/full/10.1056/NEJMoa2302392. CODE and 28 ...

F

AAEPL | Lille

Facebook

org/doi/full/10.1056/NEJMoa2302392 · May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE · May be a doodle of text that says 'ORFORELIFRON ...

B

Neues vom Kongress der Amerikanischen Diabetes-Assoziation ...

Blogs

DOI: 10.1056/NEJMoa2301972. (4) Sean Wharton et al.: Daily Oral GLP-1 Receptor Agonist Orfoglipron for ... DOI: 10.056/NEJMoa2302392. Posted on 2. Juli 2023 ...

I

"Lilly investe US$ 6 bilhões para ampliar produção da Orforglipron ...

Instagram

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392. ⚠️ Conteúdo ...

I

[Commission Officine - Jobs étudiants] Hello tout le monde ! Aujourd ...

Instagram

... )00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. 17 hours ago · aaepl_lille. •. Follow.

org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...

org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...

I

[Commission Internat, Industrie, Recherche - Diabète et obésité] Eli ...

Instagram

... /journals/lancet/article/PIIS0140-6736(21)00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392".

I

Recap prescription analogue GLP-1. (À titre informatif, ⚠️consulter ...

Instagram

... )00213-0/abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. December 4. amande_naturopathe. •. Follow.

N

What is orforglipron?

News

DOI: 10.1056/NEJMoa2302392; Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile ...

2023; 10.1056/NEJMoa2302392. -คลังข้อมูลยา(Drug information center)คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล อ่านเพิ่มเติมได้ที่ : https://www ...

N

How Oral GLP-1 Drugs Work For Weight Loss

News

DOI:10.1056/NEJMoa2302392, https://www.nejm.org/doi/full/10.1056/NEJMoa2302392; Moiz, A., Filion, K. B., Tsoukas, M. A., et al. (2025). The ...

N

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

News

DOI:10.1056/NEJMoa2302392, https://www.nejm.org/doi/10.1056/NEJMoa2302392. Further Reading. All Glucagon-like Peptide-1 Content · How Oral GLP-1 ...

N

Medical Management of Obesity: A Comprehensive Review of Food ...

News

10.1056/NEJMoa2302392; Jastreboff AM, Kaplan LM, Frías JP, et al.: Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial ...

Y

Weight Loss GLPs 2.0 Core Series / The Functional Code Podcast ...

YouTube

... 10.1056/NEJMoa2032183 DOI: 10.1056/NEJMoa2307563 DOI ... Resources: DOI: 10.1056/NEJMoa1603827 DOI: 10.1056/NEJMoa2302392 DOI: 10.1056 ...

I

Saxenda (liraglutide), Wegovy (sémaglutide), Mounjaro (tirzépatide ...

Instagram

https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. December 4 · dr_jennettewatts's profile picture.

F

La farmacéutica Eli Lilly afirma que su píldora orforglipron cumple ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

R

Lilly makes billions of their weight loss pill Orforglipron before filing ...

Reddit

https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants ...

F

[Happy hour de la recherche] Science, rencontres & convivialité au ...

Facebook

org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...

I

Antes de gravar cada vídeo, eu lembro do impacto que uma simples ...

Instagram

DOI: 10.1056/NEJMoa2302392. RT: Dr. Leonardo Matthew - CRM-BA 31460 | CRM-SP 240346 (Este conteúdo tem caráter meramente educativo e não ...

I

Lilly annonce l'arrêt de plusieurs insulines Le laboratoire Lilly a ...

Instagram

... www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 comments. 2 days ago · whatsupdoc_mag's profile picture. whatsupdoc_mag. •. Follow.

F

[AAEPL – Présentation du Bureau] Bonjour tout le monde La ...

Facebook

org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...

I

Quando estávamos nos arrumando neste dia, eu me senti estranho ...

Instagram

DOI: 10.1056/NEJMoa2302392. RT: Dr. Leonardo Matthew - CRM-BA 31460 | CRM-SP 240346 (Este conteúdo tem caráter meramente educativo e não ...

N

Oral Semaglutide 25 mg and Orforglipron for Obesity: New NEJM ...

News

Wharton S, Blevins T, Connery L, et al. The New England Journal of Medicine. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392. Oral Semaglutide ...

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

The once-daily oral GLP-1 RA orforglipron produces clinically and ...

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

I

Une pilule contre l'obésité ? Les injections GLP-1 (wegovy ...

Instagram

... 10.1056/NEJMoa2511774#:~:text=Conclusions,other%20GLP%2D1 ... https://www.nejm.org/doi/full/10.1056/NEJMoa2302392. more. View all 4 ...

F

The NEJM just reported impressive weight loss with Orforglipron, the ...

Facebook

Page 1 of "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. 698 reactions ·. 23 comments. ·. 172 shares. Euronews Next.

I

Swissmedic met en garde contre des produits « GLP-1 » falsifiés et ...

Instagram

... 10.1056/NEJMoa2302392. more. View all 4 comments. December 4 · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy.

I

Managing obesity and type 2 diabetes is complex, but ... - Instagram

Instagram

15150 [747] doi:10.1056/NEJMoa2302392 [748] doi:10.1007/s13300-024-01554-1 [749] doi: ...

F

Las pastillas orforglipron se encuentran en la fase III de sus estudios ...

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

R

Lillys dagliga GLP-1 piller för viktminskning avslutar fas 3-studier : r ...

Reddit

För jämförelse, i fas 2-studierna (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36 mg ledde till 13,5% viktminskning efter bara 36 ...

R

ATTAIN-1基础结果公布：Lilly的每日GLP-1减肥药物完成第三期试验

Reddit

相比之下，在第二期试验中（https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36毫克在36周后导致13.5%的体重减轻，而45毫克导致14.7%的体重减轻。

R

릴리의 체중 감량용 경구 GLP-1 약물, 3상 임상 시험 완료 : r/Zepbound

Reddit

비교를 위해 2상 시험에서 (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), ) 36mg은 36주 만에 13.5%의 감소를 보였고, 45mg은 14.7%의 ...

R

Lilly 的每日GLP-1 減重藥丸完成第3 期臨床試驗: r/Zepbound - Reddit

Reddit

作為比較，在第2 期試驗中（https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36mg 在僅36 週後導致減重13.5%，而45mg 則導致減重14.7%。 這是 ...

R

قرص روزانه GLP-1 لیلی برای کاهش وزن، آزمایشات فاز 3 را تکمیل کرد ...

Reddit

برای مقایسه، در آزمایشات فاز 2 (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36 میلی گرم منجر به 13.5% کاهش وزن پس از تنها 36 هفته ...

R

ATTAIN-1 Topline results released: Lilly's daily GLP-1 pill for weight ...

Reddit

For comparison, in the Phase 2 trials (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392), 36mg led to 13.5% loss after just 36 weeks, and ...

B

Uncategorized | New Drug Approvals | Page 9

Blogs

The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564. ^ Jump up to: ...

B

Orforglipron' | New Drug Approvals

Blogs

The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564. ^ Jump up to: ...

N

What is orforglipron? - Universal Drugstore

News

... 10.1056/NEJMoa2302392; HCP Live: https://www.hcplive.com/view/orforglipron-shows-promise-as-weight-loss-diabetes-agent-in-phase-2-trials ...

F

Orforglipron - Facebook

Facebook

org/doi/full/10.1056/NEJMoa2302392?query=featur ed_home. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Carmen ...

F

Orforglipron reduces HbA1c and weight in type 2 diabetes - Facebook

Facebook

-Paper #2 (Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity): From September 2021 through late November 2022, a total ...

F

[Commission Pharm'anim - barbecue de fin d'année] Salut tout le ...

Facebook

org/doi/full/10.1056/NEJMoa2302392. May be an image of text that says 'LA NEWS INDUS: ELI LILLY ENTRE. May be a doodle of text that says ...

F

‏أول حبّة GLP-1 فموية غير ببتيدية لتنزيل #الوزن و #السكر ...

Facebook

... Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity دراسة من المرحلة الثانية (عشوائية ومزدوجة التعمية) شملت 272 شخص ...

L

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

LinkedIn

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM.

I

See how Orforglipron compares to what we currently have on the ...

Instagram

... 10.1056/NEJMoa2302392 VOL. 389 NO. 10 (I edited the original graphic from Molecular Metabolism 2021 to add Mounjaro and orforglipron and put ...

org/doi/full/10.1056/NEJMoa2302392)라는 2상 임상시험 결과를 발표했는데, 이는 세마글루타이드의 결과와 거의 비슷한 수준이다. (2) 화이자의 후보 ...

F

禮來口服減肥藥後期試驗成功 ‍⚕️ #新一代禮來藥廠口服減重藥物 ...

Facebook

... 10.1056/NEJMoa2302392. Online ahead of print. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Log in ·